PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab - Loibl, S; Majewski, I; Guarneri, V (Annals of oncology : official journal of the European Society for Medical Oncology, 2016)
et al.